01.002 RWE APR 2022 BS A

Real world evidence findings of management of acute bacterial skin and skin structure infections (ABSSSI)

  • The treatment of acute bacterial skin and skin structure infections (ABSSSI) can be limited due to antimicrobial resistance by bacteria
  • Levonadifloxacin has unique multispectrum antimicrobial coverage and is indicated in ABSSSI, diabetic foot ulcers, and concurrent bacteremia
  • 79 out of 227 patients were identified to have MRSA isolates; and clinical success rates with oral, IV, and IV followed by oral levonadifloxacin therapy were 97.3%, 97.8%, and 100% respectively
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at